文献速递神经肿瘤

荧光引导胶质瘤手术的荧光剂:临床前与临床结果的系统综述

Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results.
PubMed 文献 · Acta Neurochir (Wien) · 2016-11-22

该系统综述检索截至2016年3月的PubMed和Embase数据库,共纳入105篇文章,评估5-氨基乙酰丙酸(5-ALA)、荧光素、吲哚菁绿、金丝桃素、5-氨基荧光素-人血清白蛋白、内源性荧光团及临床前阶段荧光剂在胶质瘤荧光引导手术中的应用。5-ALA是唯一经随机对照试验验证的荧光剂,可改善高级别胶质瘤的全切除率和无进展生存期;荧光素的观察性研究提示相似结果;分子靶向荧光剂仍处于临床前阶段。

要点

  • 5-ALA是唯一经随机对照试验验证的荧光剂,可改善高级别胶质瘤的全切除率和无进展生存期。
  • 荧光素的观察性队列研究和病例系列提示与5-ALA相似的结果。
  • 分子靶向荧光剂(如抗EGFR抗体标记的荧光团/纳米颗粒)仍处于临床前阶段,结果 promising,可能成为未来有价值的替代选择。

核心结论

  • 5-ALA是唯一经随机对照试验验证的荧光剂,可改善高级别胶质瘤的全切除率和无进展生存期。
  • 荧光素的观察性队列研究和病例系列提示相似结果。
  • 分子靶向荧光剂仍处于临床前阶段,结果 promising,可能成为未来有价值的替代选择。

研究设计与样本

  • 系统综述,检索PubMed和Embase数据库截至2016年3月的所有相关研究。
  • 初检2155篇文章经标题和摘要筛选,全文筛选后105篇符合纳入标准。
  • 纳入研究评估的荧光剂包括:5-ALA(44项研究,含3项随机对照试验)、荧光素(11项)、吲哚菁绿(5项)、金丝桃素(2项)、5-氨基荧光素-人血清白蛋白(1项)、内源性荧光团(9项)及临床前阶段荧光剂(30项),另识别3项Meta分析。

主要发现

  • 5-ALA是唯一经随机对照试验验证的荧光剂,可改善高级别胶质瘤的全切除率和无进展生存期。
  • 荧光素的观察性队列研究和病例系列提示相似结果。
  • 分子靶向荧光剂(如抗EGFR抗体标记的荧光团/纳米颗粒)仍处于临床前阶段,结果 promising,可能成为未来有价值的替代选择。

关键数值与推荐

  • 评估荧光剂的结局指标包括:全切除率、总生存期和无进展生存期、区分肿瘤与健康脑组织的敏感性和特异性、荧光信号肿瘤与正常组织比值、不良事件发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluorescence-guided surgery (FGS) is a technique used to enhance visualization of tumor margins in order to increase the extent of tumor resection in glioma surgery. In this paper, we systematically review all clinically tested fluorescent agents for application in FGS for glioma and all preclinically tested agents with the potential for FGS for glioma. METHODS: We searched the PubMed and Embase databases for all potentially relevant studies through March 2016. We assessed fluorescent agents by the following outcomes: rate of gross total resection (GTR), overall and progression-free survival, sensitivity and specificity in discriminating tumor and healthy brain tissue, tumor-to-normal ratio of fluorescent signal, and incidence of adverse events. RESULTS: The search strategy resulted in 2155 articles that were screened by titles and abstracts. After full-text screening, 105 articles fulfilled the inclusion criteria evaluating the following fluorescent agents: 5-aminolevulinic acid (5-ALA) (44 studies, including three randomized control trials), fluorescein (11), indocyanine green (five), hypericin (two), 5-aminofluorescein-human serum albumin (one), endogenous fluorophores (nine) and fluorescent agents in a pre-clinical testing phase (30). Three meta-analyses were also identified. CONCLUSIONS: 5-ALA is the only fluorescent agent that has been tested in a randomized controlled trial and results in an improvement of GTR and progression-free survival in high-grade gliomas. Observational cohort studies and case series suggest similar outcomes for FGS using fluorescein. Molecular targeting agents (e.g., fluorophore/nanoparticle labeled with anti-EGFR antibodies) are still in the pre-clinical phase, but offer promising results and may be valuable future alternatives.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Senders JT, Muskens IS, Schnoor R, et al. Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results. Acta Neurochir (Wien). 2016. PMID: 27878374. doi:10.1007/s00701-016-3028-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。